Evropska unija - slovenščina - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle cell - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Evropska unija - slovenščina - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. pri odraslih bolnikih, za pomoč pri razlikovanju verjetno, demenco z lewy organe, od alzheimerjeve bolezni.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - druga zdravila na živčnem sistemu - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Evropska unija - slovenščina - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastična sredstva - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

proveca pharma limited - enalapril (maleate) - odpoved srca - sredstva, ki delujejo na sistem renin-angiotenzin - treatment of heart failure.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astellas pharma d.o.o. - solifenacin - filmsko obložena tableta - solifenacin 7,5 mg / 1 tableta - solifenacin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astellas pharma d.o.o. - solifenacin - filmsko obložena tableta - solifenacin 3,8 mg / 1 tableta - solifenacin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 100 mg / 1 viala - pemetreksed

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 1000 mg / 1 viala - pemetreksed

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astellas pharma d.o.o. - solifenacin - peroralna suspenzija - solifenacin 0,75 mg / 1 ml - solifenacin